文献速递主动脉疾病内脏/肾动脉与血管畸形

开窗腔内修复术治疗累及内脏血管的腹主动脉瘤30天结局优于开放手术

Thirty-day outcomes after fenestrated endovascular repair are superior to open repair of abdominal aortic aneurysms involving visceral vessels.
PubMed 文献 · J Vasc Surg · 2017-07-13

基于NSQIP 2008-2013数据库,比较开窗腔内修复术(FEVAR,n=535)与开放手术(OS,n=1207)治疗累及内脏血管的腹主动脉瘤的30天结局。FEVAR组术后肺部并发症、需透析的肾衰竭、心脏骤停或心梗、大输血、重返手术室及死亡均显著低于OS组,住院时间更短;多因素分析显示OS与更高的30天死亡及不良事件风险相关。

要点

  • FEVAR组30天死亡2.4%,OS组4.7%(P=.02)
  • FEVAR组肺部并发症3.0%,OS组19.0%(P<.0001)
  • FEVAR组需透析肾衰竭1.9%,OS组6.4%(P<.0001)

核心结论

  • 对于累及内脏血管的腹主动脉瘤,FEVAR相比OS与更低的30天死亡率和不良事件风险相关。

研究设计与样本

  • 回顾性多机构队列研究,数据来自美国外科医师学会NSQIP 2008至2013数据库。
  • 纳入择期治疗的累及内脏血管的腹主动脉瘤患者,FEVAR组535例,OS组1207例;排除胸腹主动脉瘤。
  • 采用单因素和多因素logistic回归分析比较30天结局。

主要发现

  • FEVAR组男性比例82% vs OS组72%(P<.0001),糖尿病16% vs 11%(P=.005),依赖功能状态4% vs 2%(P=.002),不吸烟70% vs 56%(P<.0001)。
  • FEVAR组主要术后肺部并发症3.0% vs 19.0%(P<.0001),需透析的肾衰竭1.9% vs 6.4%(P<.0001),心脏骤停或心梗2.2% vs 5.8%(P=.001)。
  • FEVAR组大输血17.4% vs 50.2%(P<.0001),重返手术室4.5% vs 9.6%(P<.0001),死亡2.4% vs 4.7%(P=.02)。
  • FEVAR组中位住院时间2天 vs 7天(P<.0001)。
  • 多因素分析显示OS相比FEVAR的30天死亡OR=2.6(95%CI 1.3-5.0),肺部并发症OR=8.8(95%CI 5.1-15.0),心脏并发症OR=3.4(95%CI 1.8-6.6),需透析肾衰竭OR=3.8(95%CI 1.9-7.7),重返手术室OR=2.5(95%CI 1.6-4.0)。

临床怎么用

  • 对于择期治疗累及内脏血管的腹主动脉瘤,FEVAR可作为降低30天死亡及主要并发症风险的优选方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although few studies have reported outcomes after branched or fenestrated endovascular aortic aneurysm repair (FEVAR) of abdominal aortic aneurysms involving visceral vessels (AAA-Vs), no multi-institutional study has compared FEVAR with open surgery (OS) for AAA-Vs. Our objective was to compare 30-day outcomes after FEVAR vs OS for AAA-Vs. METHODS: Patients who underwent FEVAR (n = 535) and OS (n = 1207) for elective AAA-Vs were identified from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) 2008 to 2013 database. Thoracoabdominal aneurysms were excluded. Univariable and multivariable logistic regression analyses were performed. RESULTS: There were more men (82% vs 72%; P < .0001), diabetic patients (16% vs 11%; P = .005), patients with dependent functional status (4% vs 2%; P = .002), and nonsmokers (70% vs 56%; P < .0001) in the FEVAR group vs OS. There was no difference in rates of chronic obstructive pulmonary disease, cardiac history, peripheral artery disease, hypertension, and dialysis (P > .05). FEVAR had fewer major postoperative pulmonary complications (3.0% vs 19.0%; P < .0001), less renal failure requiring dialysis (1.9% vs 6.4%; P < .0001), less frequent cardiac arrest or myocardial infarction (2.2% vs 5.8%; P = .001), less bleeding with major transfusion (17.4% vs 50.2%; P < .0001), and decreased incidence of return to the operating room (4.5% vs 9.6%; P < .0001) and death (2.4% vs 4.7%; P = .02). The median length of stay was also significantly shorter for FEVAR (2 days vs 7 days; P < .0001). On multivariable analyses, OS was associated with higher risk than FEVAR for 30-day death (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.3-5.0), pulmonary complications (OR, 8.8; 95% CI, 5.1-15.0), cardiac complications (OR, 3.4; 95% CI, 1.8-6.6), renal failure needing dialysis (OR, 3.8; 95% CI, 1.9-7.7), and return to the operating room (OR 2.5; 95% CI, 1.6-4.0). CONCLUSIONS: FEVAR is associated with a lower risk for 30-day mortality and adverse events compared with OS for AAA-Vs.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gupta PK, Brahmbhatt R, Kempe K, et al. Thirty-day outcomes after fenestrated endovascular repair are superior to open repair of abdominal aortic aneurysms involving visceral vessels. J Vasc Surg. 2017. PMID: 28711400. doi:10.1016/j.jvs.2017.04.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。